Healthcare -
Biotechnology - NASDAQ - US
$ 24.2
-13.6 %
$ 17.9 B
Market Cap
-71.18
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Summit Therapeutics Inc.
| Net Income | -221 M |
| Depreciation & Amortization | 89 K |
| Capital Expenditures | -139 K |
| Stock-Based Compensation | 51 M |
| Change in Working Capital | 15.5 M |
| Others | 25.6 M |
| Free Cash Flow | -142 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Jan-2019 | Jan-2018 | Jan-2017 | Jan-2016 | Jan-2015 | Jan-2014 | Jan-2013 | Jan-2012 | Jan-2011 | Jan-2010 | Jan-2009 | Jan-2008 | Jan-2007 | Jan-2006 | Jan-2005 | Jan-2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||||||||||||
| Net Income | (221.3) | (614.9) | (78.8) | (88.6) | (52.7) | (23.9) | 6.6 | (15.4) | (32.1) | (28.7) | (19.1) | (11.1) | (7.2) | (4.7) | (9.4) | (6.8) | (35.1) | (23.4) | (8.6) | (3.2) | (0.5) | 43.8 K |
| Depreciation & Amortization | 89 K | 2.0 | 2.5 | 2.5 | 2.0 | 1.4 | 1.5 | 0.3 | 72.5 K | 68.4 K | 49.7 K | 42.9 K | 0.1 | 0.3 | 0.7 | 3.8 | 2.7 | 3.3 | 0.7 | 0.2 | 9.41 K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0.3 | 0.6 | 0.3 | 2.97 | 0 | 4.7 | 1.8 | 1.2 | 0.4 | 1.8 | 0.4 | 2.0 | 1.2 | 1.5 | 3.3 | 2.7 | 0.4 | 0 | 0 |
| Stock Based Compensation | 51.0 | 14.1 | 9.9 | 9.5 | 1.3 | 0.5 | 6.2 | 2.3 | 1.7 | 1.7 | 1.4 | 0.4 | 0.2 | 97.4 K | 0.1 | 28.8 K | 0.3 | 1.0 | 0.8 | 0.1 | 0 | 0 |
| Other Operating Activities | 12.7 | 524.4 | 14.1 | 0.5 | (0.4) | 5.1 | 1.7 | 3.5 | 1.1 | (0.1) | (0.1) | 0.3 | 1.8 | 0.5 | 0.6 | (0.6) | 1.5 | 0.8 | 0.3 | 51.8 K | 0.000001 | (0.1) |
| Change in Working Capital | 15.5 | (2.4) | 8.6 | 67 K | 0.6 | 1.0 | (51.2) | (11.5) | 39.8 | 0.8 | (0.5) | 0.7 | 63.2 K | 44 K | 3.6 | 1.0 | 15.9 | 2.2 | 0.8 | 0.3 | 0.2 | 0.1 |
| Cash From Operations | (142.1) | (76.8) | (41.6) | (72.6) | (48.1) | (15.6) | (35.1) | (20.8) | 15.2 | (24.5) | (17.1) | (9.7) | (5.0) | (3.8) | (4.3) | (2.6) | (14.7) | (16.1) | (6.0) | (2.5) | (0.3) | 1.82 K |
| INVESTING CASH FLOW | ||||||||||||||||||||||
| Capital Expenditures | (0.1) | (0.1) | (0.6) | (0.3) | (0.4) | (0.3) | (0.2) | (0.7) | (0.1) | 94 K | 52.7 K | 77.5 K | (0.1) | (0.2) | (0.2) | (0.1) | (1.7) | (3.9) | (3.4) | (2.5) | 11.3 K | 0 |
| Other Items | (205.2) | (587.6) | 0 | 0 | 0 | 0 | (0.2) | (6.7) | 10 K | 42.7 K | 76.8 K | 0.2 | 17.4 K | 17.3 K | 22.2 K | 25.6 K | 0.4 | 2.3 | 1.0 | 4.8 | (25.6) | 0 |
| Cash From Investing Activities | (205.3) | (587.8) | (0.6) | (0.3) | (0.4) | (0.3) | (0.4) | (7.4) | 100 K | 51.3 K | 24.1 K | 0.1 | (0.1) | (0.2) | (0.2) | (0.1) | (1.2) | (1.5) | (2.3) | 2.4 | (25.6) | 0 |
| FINANCING CASH FLOW | ||||||||||||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (100.0) | (24.7) | 520.0 | 0 | 0 | 0 | (0.4) | (0.2) | 23 K | 0 | (0.3) | 0 | 0 | 0 | 0 | 84.7 K | (0.3) | 1.1 | (0.2) | 1.4 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.3 | 106.2 | 100.2 | 2.9 | 0.6 | 37.5 | (1.2) | (7.0) | 0.5 | (5.6) | (1.9) | (3.2) | (0.7) | (0.9) | 6.33 K | (0.9) | 14.4 K | 1 | 0.0981 | 0 | 0 | 0.2 |
| Cash From Financing Activities | 381.2 | 86.5 | 620.2 | 77.9 | 50.6 | 37.5 | 43.9 | 19.7 | 0.5 | 22.1 | 31.0 | 7.4 | 7.2 | 2.1 | 22.2 K | 8.1 | 5.3 | 1.3 | 19.4 | 1.3 | 26.5 | 0.2 |
| CHANGE IN CASH | ||||||||||||||||||||||
| Net Change In Cash | 33.8 | (577.2) | 576.8 | 5.4 | 2.6 | 27.7 | 8.9 | (11.3) | 14.7 | 7.2 | 13.9 | (2.2) | 2.1 | (1.8) | (4.5) | 5.4 | (10.6) | (16.3) | 11.1 | (20.0) | (25.6) | 0.2 |
| FREE CASH FLOW | ||||||||||||||||||||||
| Free Cash Flow | (142.2) | (76.9) | (42.2) | (72.9) | (48.5) | (15.8) | (35.3) | (21.5) | 15.1 | (24.6) | (17.1) | (9.8) | (5.2) | (4.0) | (4.5) | (2.8) | (16.4) | (20.0) | (9.3) | (5.0) | (0.4) | 1.82 K |